Elizabeth Eisenhauer
Overview
Explore the profile of Elizabeth Eisenhauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
16065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Eisenhauer E
J Obstet Gynecol Neonatal Nurs
. 2024 Apr;
53(3):207-212.
PMID: 38583485
Nurses need to understand how clinical genetic and genomic applications affect newborn screening and advocate for parents and newborns.
3.
Walker R, Eisenhauer E, Thompson E, Butler R, Metheny N, Barroso C, et al.
Am J Public Health
. 2024 Jan;
114(S1):S112-S123.
PMID: 38207271
To provide initial findings from Community Engagement Alliance (CEAL), a multistate effort funded by the National Institutes of Health, to conduct urgent community-engaged research and outreach focused on COVID-19 awareness,...
4.
Eisenhauer E
J Obstet Gynecol Neonatal Nurs
. 2023 Apr;
52(3):172-177.
PMID: 37060919
The Associate Editor provides useful suggestions for authors on writing review articles.
5.
Gyawali B, Eisenhauer E, Brundage M
JAMA Oncol
. 2022 Aug;
8(10):1517-1518.
PMID: 36006636
No abstract available.
6.
Robinson A, ODonnell J, Booth C, Koven R, Eisenhauer E, Brundage M
J Cancer Policy
. 2022 May;
30:100301.
PMID: 35559797
Background: Progression-free survival (PFS) is often used as a clinical trials outcome for evaluating new therapies for solid tumors. While PFS is a validated surrogate for overall survival (OS) or...
7.
Samuel J, Booth C, Eisenhauer E, Brundage M, Berry S, Gyawali B
JAMA Oncol
. 2022 Apr;
8(6):879-886.
PMID: 35482347
Importance: Although quality of life (QOL) is an important clinical end point, cancer drugs are often approved based on overall survival (OS) or putative surrogate end points such as progression-free...
8.
Gyawali B, Eisenhauer E, Tregear M, Booth C
Lancet Oncol
. 2022 Mar;
23(3):328-330.
PMID: 35240080
No abstract available.
9.
Thomas G, Eisenhauer E, Bristow R, Grau C, Hurkmans C, Ost P, et al.
Eur J Cancer
. 2020 Apr;
131:76-88.
PMID: 32305726
Background: New technologies and techniques in radiation oncology and imaging offer opportunities to enhance the benefit of loco-regional treatments, expand treatment to new patient populations such as those with oligometastatic...
10.
Raphael M, Robinson A, Booth C, ODonnell J, Palmer M, Eisenhauer E, et al.
JAMA Oncol
. 2019 Sep;
5(12):1779-1789.
PMID: 31556921
Importance: It is unclear whether patients with advanced cancer value surrogate end points, particularly progression-free survival (PFS). Despite this uncertainty, surrogate end points form the basis of regulatory approval for...